Oregon Health & Science University
Portland, Oregon, 97201, United States
NCT Number: NCT00765310
The purpose of this study is to see if a dietary supplement, R-alpha lipoic acid, is able to reduce risk factors such as body weight and high blood cholesterol levels in overweight or obese participants.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 1
Portland, Oregon, 97201, United States
The purpose of this study is to see if a dietary supplement, R-alpha lipoic acid, is able to reduce risk factors such as body weight and high blood cholesterol levels in overweight or obese participants.
Recruitment will be in the Portland, Oregon area.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
600 mg in morning on empty stomach (two 300 mg capsules)
Other names: Thioctic acid, LA, lipoic acid
two capsules once daily in morning on empty stomach
Time frame: 12 weeks and 24 weeks
Time frame: 12 and 24 weeks
Time frame: 12 and 24 weeks
Oregon State University
Other
The Role of R-alpha Lipoic Acid in Prevention of Atherosclerotic Vascular Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00764270
Arterial Occlusive Diseases, Arteriosclerosis
Portland, Oregon, United States
View Trial DetailsNCT01461226
Arterial Occlusive Diseases, Arteriosclerosis
De Haan, Belgium
View Trial DetailsNCT04598685
Arterial Occlusive Diseases, Arteriosclerosis
Innsbruck, Tyrol, Austria
View Trial DetailsNCT04760951
Arterial Occlusive Diseases, Arteriosclerosis
Lille, France
View Trial Details